These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6769666)

  • 21. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.
    Bialer M; Rubinstein A; Raz I; Abramsky O
    Eur J Clin Pharmacol; 1984; 27(4):501-3. PubMed ID: 6440792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased dipropylacetic acid bioavailability from dipropylacetamide by food.
    Pisani F; D'Agostino AA; Fazio A; Oteri G; Primerano G; Di Perri R
    Epilepsia; 1982 Apr; 23(2):115-21. PubMed ID: 6804222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.
    Battino D; Biraghi M; Cusi C; Nespolo A; Avanzini G
    Ital J Neurol Sci; 1982 Oct; 3(3):197-200. PubMed ID: 6819250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronopharmacokinetic study of valproic acid in man: comparison of oral and rectal administration.
    Yoshiyama Y; Nakano S; Ogawa N
    J Clin Pharmacol; 1989 Nov; 29(11):1048-52. PubMed ID: 2513338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads.
    Damle BD; Yan JH; Behr D; O'Mara E; Nichola P; Kaul S; Knupp C
    J Clin Pharmacol; 2002 Apr; 42(4):419-27. PubMed ID: 11936567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability in absorption lag time of pyridoxal phosphate under fasting and pre- and post-meal conditions.
    Takahashi H; Ogata H; Nagai N; Sugito K; Shimamura H
    Biopharm Drug Dispos; 1994 Aug; 15(6):505-17. PubMed ID: 7993988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt.
    Glazko AJ; Chang T; Daftsios AC; Eiseman I; Smith TC; Buchanan RA
    Ther Drug Monit; 1983; 5(4):409-17. PubMed ID: 6419419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cholestyramine resin on single dose valproate pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Diskin CJ
    Int J Clin Pharmacol Ther; 1996 May; 34(5):208-11. PubMed ID: 8738857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
    Ahmad M; Pervaiz F
    Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
    Dutta S; Reed RC
    Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some clinical pharmacological aspects of n-dipropylacetamide.
    Pisani F; Di Perri R
    Ital J Neurol Sci; 1980 Oct; 1(4):245-9. PubMed ID: 6802780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation.
    Retzow A; Vens-Cappell B; Wangemann M
    Arzneimittelforschung; 1997 Dec; 47(12):1347-50. PubMed ID: 9450162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets].
    Walter K; von Nieciecki A
    Arzneimittelforschung; 2001; 51(8):643-50. PubMed ID: 11556125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions.
    Thomson AB; Sinclair P; Matisko A; Rosen E; Andersson T; Olofsson B
    Can J Gastroenterol; 1997; 11(8):663-7. PubMed ID: 9459045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
    González MA; Straughan AB
    Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of food on valproic acid absorption.
    Hamilton RA; Garnett WR; Kline BJ; Pellock JM
    Am J Hosp Pharm; 1981 Oct; 38(10):1490-3. PubMed ID: 6794365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Is it preferable to prescribe 1 or 2 daily doses of sodium valproate?].
    Loiseau P; Levy RH; Guyot M; Morselli PL; Brachet-Liermain A
    Nouv Presse Med; 1982 Dec; 11(50):3693-6. PubMed ID: 6820492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.